Xvivo Perfusion

Xvivo Perfusion XVIPF Stock

$20.05   0.000000%
Add to favorites
Market Cap
$631.56M
LOW - HIGH [24H]
$21.80 - $21.80
VOLUME [24H]
$592.00
P/E Ratio
45.56
Earnings per share
$0.44
ISIN
SE0004840718
Price   Prediction

Xvivo Perfusion Price Chart

Sorry, that's all we've gotfor now...

Xvivo Perfusion (XVIPF) stock price today is 20.05 USD on OTC Markets OTCPK (0% on the day). Updated .

Xvivo Perfusion XVIPF Financial and Trading Overview

Xvivo Perfusion stock price 20.05 USD
Previous Close 20.05 USD
Open 21.8 USD
Bid 19.96 USD x 10000
Ask 20.56 USD x 10000
Day's Range 21.8 - 21.8 USD
52 Week Range 17.46 - 30.95 USD
Volume 592 USD
Avg. Volume 68 USD
Market Cap 631.56M USD
Beta (5Y Monthly) 1.472
PE Ratio (TTM) 45.56818
EPS (TTM) 0.44 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est N/A

XVIPF Valuation Measures

Enterprise Value N/A
Trailing P/E 45.56818
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) N/A
Price/Book (mrq) 0.30164436
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA N/A

Trading Information

Xvivo Perfusion Stock Price History

Beta (5Y Monthly) 1.472
52-Week Change 14.86%
S&P500 52-Week Change 13.08%
52 Week High 30.95 USD
52 Week Low 17.46 USD
50-Day Moving Average 24.07 USD
200-Day Moving Average 24.83 USD

XVIPF Share Statistics

Avg. Volume (3 month) 68 USD
Avg. Daily Volume (10-Days) 48 USD
Shares Outstanding 31.5M
Float 25.13M
Short Ratio N/A
% Held by Insiders 8.32%
% Held by Institutions 60.71%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 13.44%
Operating Margin (ttm) 0%
Gross Margin 71.17%
EBITDA Margin 18.66%

Management Effectiveness

Return on Assets (ttm) 3.21%
Return on Equity (ttm) 5.91%

Income Statement

Revenue (ttm) N/A
Revenue Per Share (ttm) N/A
Quarterly Revenue Growth (yoy) 33.50%
Gross Profit (ttm) N/A
EBITDA 178.94M USD
Net Income Avi to Common (ttm) N/A
Diluted EPS (ttm) 0.44
Quarterly Earnings Growth (yoy) 928.10%

Balance Sheet

Total Cash (mrq) N/A
Total Cash Per Share (mrq) N/A
Total Debt (mrq) N/A
Total Debt/Equity (mrq) 5.32 USD
Current Ratio (mrq) 3.915
Book Value Per Share (mrq) 66.469

Cash Flow Statement

Operating Cash Flow (ttm) N/A
Levered Free Cash Flow (ttm) 2.51M USD

Profile of Xvivo Perfusion

Country United States
State N/A
City Mölndal
Address Gemenskapens gata 9
ZIP 431 53
Phone 46 3 17 88 21 50
Website https://www.xvivogroup.com
Industry Medical Devices
Sector(s) Healthcare
Full Time Employees 207

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.

Q&A For Xvivo Perfusion Stock

What is a current XVIPF stock price?

Xvivo Perfusion XVIPF stock price today per share is 20.05 USD.

How to purchase Xvivo Perfusion stock?

You can buy XVIPF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Xvivo Perfusion?

The stock symbol or ticker of Xvivo Perfusion is XVIPF.

Which industry does the Xvivo Perfusion company belong to?

The Xvivo Perfusion industry is Medical Devices.

How many shares does Xvivo Perfusion have in circulation?

The max supply of Xvivo Perfusion shares is 31.5M.

What is Xvivo Perfusion Price to Earnings Ratio (PE Ratio)?

Xvivo Perfusion PE Ratio is 45.56818000 now.

What was Xvivo Perfusion earnings per share over the trailing 12 months (TTM)?

Xvivo Perfusion EPS is 0.44 USD over the trailing 12 months.

Which sector does the Xvivo Perfusion company belong to?

The Xvivo Perfusion sector is Healthcare.

$2.35T
Total marketcap
$96.01B
Total volume
BTC 58.94%   •   ETH 10.14%
Dominance
Select currency